We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 07, 2021

18F-FES and 18F-FDG PET for Prediction of PFS After Fulvestrant Therapy in Patients With HR+/HER2− MBC

Frontiers in Oncology

 

Additional Info

Frontiers in Oncology
Dual Tracers of 16α-[18F]Fluoro-17β-Estradiol and [18F]Fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer
Front Oncol 2020 Dec 01;[EPub Ahead of Print], C Liu, X Xu, H Yuan, Y Zhang, Y Zhang, S Song, Z Yang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading